PCI Biotech Calls Meeting to Vote on Dissolution and Delisting from Oslo Børs

PCI Biotech Holding ASA ( (DE:4QG) ) has provided an announcement.

PCI Biotech Holding ASA has called an extraordinary general meeting for 16 March 2026 at its Oslo Cancer Cluster Innovation Park offices, where shareholders will vote on proposals to dissolve the company and delist its shares from Euronext Oslo Børs. The board cites the absence of any current or expected future operational activity, along with the company’s constrained assets, as the rationale for winding up the listed holding company and its wholly owned subsidiary PCI Biotech AS, concluding the business is no longer suitable for public trading and should exit the market swiftly.

The proposed dissolution and delisting mark a definitive end to PCI Biotech’s presence on the Norwegian stock exchange, effectively closing out remaining options for continued corporate activity. For shareholders, the move signals an impending liquidation process rather than a strategic pivot or restructuring, underscoring that management sees no viable pathway to revive operations or justify a continued listing under prevailing conditions.

More about PCI Biotech Holding ASA

PCI Biotech Holding ASA is a Norwegian biotechnology company previously focused on developing photochemical internalisation technology for improving the delivery of cancer therapeutics. The company has been listed on Euronext Oslo Børs but currently has no ongoing operational activity and a limited asset base, which has prompted a strategic reassessment of its public company status.

YTD Price Performance: -15.45%

Average Trading Volume: 216,961

Current Market Cap: NOK7.76M

For detailed information about 4QG stock, go to TipRanks’ Stock Analysis page.